Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS +0.77%93 Return-on-Tangible-Asset is 23.94% as of Jun. 2026, which is 0% above its 10-year median of 23.84. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹608.70 (Fairly Valued). The stock has 5 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 94.34% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Metropolis Healthcare's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹2,267 Mil. Metropolis Healthcare's average total tangible assets for the quarter that ended in Jun. 2026 was ₹9,470 Mil. Therefore, Metropolis Healthcare's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 23.94%.
The historical rank and industry rank for Metropolis Healthcare's Return-on-Tangible-Asset or its related term are showing as below:
NSE:METROPOLIS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 18.44 Med: 23.84 Max: 27.12
Current: 24.09
During the past 11 years, Metropolis Healthcare's highest Return-on-Tangible-Asset was 27.12%. The lowest was 18.44%. And the median was 23.84%.
NSE:METROPOLIS's Return-on-Tangible-Asset is ranked better than 94.34% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.735
vs NSE:METROPOLIS: 24.09
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Metropolis Healthcare Return-on-Tangible-Asset Related Terms
Metropolis Healthcare Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, NTRA: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 23.94% mean?
Metropolis Healthcare (NSE:METROPOLIS) has a Return-on-Tangible-Asset of 23.94% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Metropolis Healthcare and its competitors. This is near median its historical median of 23.84. Over the past decade, Metropolis Healthcare's Return-on-Tangible-Asset has ranged from 18.44 to 27.12. According to the industry distribution chart, Metropolis Healthcare ranks #12 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 5.7%.
Is Metropolis Healthcare's Return-on-Tangible-Asset too high?
Metropolis Healthcare's current Return-on-Tangible-Asset of 23.94% is near median its 10-year median of 23.84. Over the past 10 years, this metric has ranged from a low of 18.44 to a high of 27.12. Based on the distribution chart, Metropolis Healthcare ranks #12 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #12 out of 212 companies for Return-on-Tangible-Asset. This places Metropolis Healthcare in the top 6% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own Return-on-Tangible-Asset has ranged from 18.44 to 27.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Return-on-Tangible-Asset is 23.94%, which is near median its own 10-year median of 23.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹608.70, compared to a current price of ₹582.20 — trading 4.4% below its estimated fair value. The current Return-on-Tangible-Asset is 23.94%, which is near median its 10-year median of 23.84. Metropolis Healthcare's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Return-on-Tangible-Asset is 23.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹582.20 is trading 4.4% below its estimated GF Value™ of ₹608.70.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Return-on-Tangible-Asset: 23.94% (near median its 10-year median of 23.84)
GF Value™: ₹608.70 vs. price of ₹582.20 (4.4% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
